• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Epivir (lamivudine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Epivir (lamivudine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    3TC is an antiretroviral (anti-HIV) agent, which belongs to a class of drugs called nucleoside analogue reverse transcriptase inhibitors. 3TC is used in combination with other antiretrovirals to suppress the HIV. It has recently been approved for adolescents, children, and infants from three months of age. In addition, this approval also includes an important revision to the indication for use of Epivir in combination with other antiretroviral agents for the treatment of HIV infection in adults and children.

    In adults and adolescents (12 to 16 years of age) with HIV infection, Epivir is dosed as one 150 mg tablet, twice daily, administered in combination with other antiretroviral drugs. The recommended oral dose of Epivir for pediatric patients three months to 12 years of age is 4 mg/kg twice daily (up to a maximum of 150 mg twice a day) administered in combination with other antiretroviral agents.

    Side Effects

    3TC is generally well tolerated; should side effects occur, these are more likely due to your other medications. Headache, diarrhea, fatigue, and other side effects are possible; therefore report any unusual effects to your doctor or pharmacist.

    The most common side effects are gastrointestinal: upset stomach, nausea, and vomiting. A more serious side effect, neutropenia, is a blood disorder that can merit stopping therapy. Pancreatitis or inflammation of the pancreas can also occur, but is more common in children.

    Mechanism of Action

    A nucleoside analog, 3TC blocks an enzyme called reverse transcriptase which HIV needs to replicate. Thus HIV can't replicate and the virus is controlled.

    Approval Date: 1999-04-01
    Company Name: GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 15Apr

      Five Telltale Signs You’re Ready for an Electronic TMF System

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    • 06May

      The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Clinical-Trial-Brainstorming

      FDA, Industry Tackle Problem of Including Older Adults in Trials

    • ClinicalTrialNetwork-360x240.png

      National Community-Based Research Network Would Improve Reach of Trials

    • Bottleneck-360x240.png

      Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Genetic Research and IBC Oversight Requirements

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing